Professor Maya H Buch

by | 20 Jul 2022 | Manchester, Supervisors | 0 comments

Email: maya.buch@manchester.ac.uk

Research profile and key clinical specialties

Maya Buch is Professor of Rheumatology, Director of Experimental Medicine, Centre for Musculoskeletal Research, University of Manchester, and an honorary/Visiting Professor of Rheumatology, University of Leeds.

Maya oversees an inter-disciplinary clinical translational and experimental research programme with the following research themes:

  • PRECISion medicinE across the disease continuum to prevent and treat Rheumatoid Arthritis (PRECISE-RA), with a focus on personalised therapeutics in early RA and Difficult-to-Treat-Refractory disease.
  • CARDIOvascular (CV) pathology in Immune-Mediated Inflammatory Diseases (CARDIO-IMID) to identify patients at risk of CV disease, optimal detection methods and shared mechanisms of CV-IMID comorbidity.
  • Improving therapeutics and CV outcomes in Systemic Sclerosis.

Maya undertakes clinical trials, complex observational studies and linked experimental investigation to identify prognostic, mechanistic and predictive biomarkers.

She is Chair of the NIHR-Versus Arthritis UK Musculoskeletal Translational Research Collaboration and lead of the CARDIO-IMID UK Network.

Two key publications

  • Buch MH, Eyre S, McGonagle D. Persistent Inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheum 2021 Jan;17(1):17-33.
  • Plein S, Erhayiem B, Fent G, Horton S, Dumitru RB, Andrews J, Greenwood JP, Emery P, Hensor EM, Baxter P, Pavitt S, Buch MH. Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis. Ann Rheum Dis. 2020 79(11):1414-1422.

Possible research projects

Clinical phenotyping and cellular/molecular characterisation towards:

  • Stratification of immunotherapies in rheumatoid arthritis (RA)
  • Investigating early vs refractory RA disease
  • Systemic sclerosis
  • Understanding cardiovascular disease across immune mediated diseases

More information

 

 

Keywords: Musculoskeletal, rheumatoid, arthritis, biomarkers, cardiovascular, Immune-Mediated, antirheumatic, phenotyping, immunotherapies, sclerosis, Maya, Buch, Manchester

0 Comments